Merck & Co Inc (MRK)

58.82
NYSE : Health Care
Prev Close 58.79
Day Low/High 58.55 / 59.08
52 Wk Low/High 45.69 / 60.07
Avg Volume 8.87M
Exchange NYSE
Shares Outstanding 2.77B
Market Cap 162.73B
EPS 1.60
P/E Ratio 36.07
Div & Yield 1.84 (3.10%)

Latest News

Week Ahead: Fed's July Meeting Overshadows Another Busy Earnings Week

Week Ahead: Fed's July Meeting Overshadows Another Busy Earnings Week

The Federal Reserve will steal focus from another onslaught of earnings in the coming week as investors remain wary over the central bank's rate-hike timetable.

Data For Merck's Investigational Once-Daily Formulation Of ISENTRESS® (raltegravir) Show That At Week 48, A Regimen Containing The Once-Daily Dosing Formulation...

Data For Merck's Investigational Once-Daily Formulation Of ISENTRESS® (raltegravir) Show That At Week 48, A Regimen Containing The Once-Daily Dosing Formulation...

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced efficacy and safety data in previously untreated adults with HIV-1 infection for the company's investigational once-daily formulation of...

Merck Animal Health Receives FDA Approval Of BRAVECTO® (fluralaner Topical Solution) For Cats And Dogs

Merck Animal Health Receives FDA Approval Of BRAVECTO® (fluralaner Topical Solution) For Cats And Dogs

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, today announced the U.

Merck Provides Regulatory Update On Biologics Licensing Application For Investigational Agent Bezlotoxumab

Merck Provides Regulatory Update On Biologics Licensing Application For Investigational Agent Bezlotoxumab

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said that the U.

These 5 Big Stocks Are Breaking Out This Summer

These 5 Big Stocks Are Breaking Out This Summer

Earnings season is off to a good start. Here are five more stocks that could shoot higher this summer.

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.

Here's When You Should Buy Merck

Here's When You Should Buy Merck

A pullback for Merck will lead to lower entry opportunities.

Analyst: Merck's Fundamentals Don't Warrant Current Valuation

Analyst: Merck's Fundamentals Don't Warrant Current Valuation

BMO Capital Markets downgrades the pharmaceutical giant ahead of Q2 earnings as pricing pressure mounts and other potential headwinds begin to emerge.

Merck (MRK) Stock Slides, BMO Downgrades

Merck (MRK) Stock Slides, BMO Downgrades

BMO Capital Markets downgraded Merck (MRK) stock to ‘market perform’ today.

Analysts' Actions -- Groupon, Humana, Monster, Merck and More

Analysts' Actions -- Groupon, Humana, Monster, Merck and More

Here are Monday's top research calls, including upgrades for Groupon and Humana, and downgrades for Monster Beverage and Merck.

Cramer: These Stocks Are the Key to the Bull Market

Cramer: These Stocks Are the Key to the Bull Market

Let me give you the unassailable themes.

FB, AMZN and NFLX: Jim Cramer's Views

FB, AMZN and NFLX: Jim Cramer's Views

Cramer shares his views on why he thinks this market is not finished. Facebook, Amazon and Netflix are among the stocks discussed.

3 Stocks Dragging In The Drugs Industry

3 Stocks Dragging In The Drugs Industry

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Cramer: Beware the Worst Bond Money Can Buy

Cramer: Beware the Worst Bond Money Can Buy

I care about making and preserving my clients' money.

Closing Bell: Airlines Rally on Deutsche Bulls; U.S. Stocks at Records

Closing Bell: Airlines Rally on Deutsche Bulls; U.S. Stocks at Records

An earlier rally lasted through the afternoon, pushing the S&P 500 and Dow Jones Industrial Average to close at fresh records.

Merck (MRK) Stock Gaining, Cutting Research Jobs

Merck (MRK) Stock Gaining, Cutting Research Jobs

Merck (MRK) announced that it would be laying off research and development employees at three east-coast sites.

X(encor) Marks the Spot For Potential Gains

X(encor) Marks the Spot For Potential Gains

You have to be impressed by the breadth of XNCR's pipeline and significant partnerships with major players.

3 Stocks Improving Performance Of The Drugs Industry

3 Stocks Improving Performance Of The Drugs Industry

TheStreet highlights 3 stocks pushing the drugs industry higher today.

3 Vaccine Manufacturers That Investors Should Consider for Their Portfolios

3 Vaccine Manufacturers That Investors Should Consider for Their Portfolios

Pfizer, Merck and GlaxoSmithKline are all producing blockbuster vaccines and have others in their pipelines.

Merck Animal Health Expands in Brazil in Quest to Overtake Zoetis as World Animal Health Leader

Merck Animal Health Expands in Brazil in Quest to Overtake Zoetis as World Animal Health Leader

Buying a 93% stake in Vallée SA for $400 million will enable it to surpass Ourofino SA in the South American nation and enhance its chances of being first globally.

Merck (MRK) Stock Climbs After Deal With Brazilian Animal-Health Company

Merck (MRK) Stock Climbs After Deal With Brazilian Animal-Health Company

Shares of Merck (MRK) are on the rise after the company announced a $400 million acquisition.

Merck Animal Health Announces Agreement To Acquire Controlling Interest In Brazilian Animal Health Company Vallée S.A.

Merck Animal Health Announces Agreement To Acquire Controlling Interest In Brazilian Animal Health Company Vallée S.A.

Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced it has executed an agreement to acquire a controlling interest in Vallée S.

Http://www.merck.com/index.html

Http://www.merck.com/index.html

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Premier Inc.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

How Pfizer, Merck May Feel Long-Term Pinch From Brexit

How Pfizer, Merck May Feel Long-Term Pinch From Brexit

The eventual negative implications of Brexit could be greater for health care companies that have sizable exposure to Europe.

How J&J Defied Brexit and Became the Year's Top Health Care Stock

How J&J Defied Brexit and Became the Year's Top Health Care Stock

This industry stalwart has proved its mettle by outperforming not just the broader market but also its peers. Here is why it belongs in investors' portfolios.